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Background: Obesity is widely recognized as a major public health issue resulting in decrease of quality of life and development of chronic 
diseases. Lifestyle changes are not always achievable especially in long term prospect and bariatric surgery proposed for treatment of obesity is 
often related with high morbidity and mortality Ghrelin, a recently discovered neuropeptide which is predominantly produced in the gastric fundus, 
is the only known hormone stimulating food intake (orexigenic hormone). Catheter-directed Left Gastric Artery Chemical Embolization performed in 
animal models previously showed to decrease blood ghrelin levels and lead to weight loss. Here we provide our preliminary results of the First-In-
Man study of Left Gastric Artery Embolization (GAE) safety and efficacy in humans.
methods: 5 patients with different degrees of obesity underwent GAE with BeadBlock Embolic Bead 300-500μm microspheres (Biocompatibles UK 
Limited, Chapman House, Farnham Business Park, Weydon Lane Farnham, Surrey, GU9 8QL, UK). Esophagogastroscopy was performed in all patients 
before and after GAE and at 1 week follow up to rule out significant initial gastritis or ulcer and any worsening after the procedure. Blood Ghrelin 
level was also measured before the procedure as well as at 1, 2, 3 and 4 weeks follow up. Observations on Ghrelin levels and patients weight is 
planned at 3, 6 and 12 month follow up.
results: There was no case of periprocedural complications. 3 of 5 patients complained about discomfort in epigastrium during first few hours 
after procedure, but control esophagogastroscopy did not reveal any impairments. All patients reported decreased appetite during first week after 
procedure, Weight loss was observed in all patients at 1 month follow up: mean initial weight - 128.12±24.4kg was decreased to 114.86±21.3kg 
and mean initial Body Mass Index (BMI) - 42.26±6.8 was decreased to 37.86±5.7. 6 moth follow-up results of GAE will be available at time of 
presentation.
conclusions: Short term follow up has shown that GAE is safe and feasible. Further studies enrolling larger number of patients are planned to 
confirm these initial findings.
